Annexon (ANNX) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Annexon (ANNX) has outperformed Kura Oncology (KURA) over the past year, losing 27.4% versus a loss of 38.1%. Over five years, KURA leads with a -50.7% price change compared with -77.4% for ANNX. Kura Oncology is the larger company by market cap ($634.9 million vs $591.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | KURA |
|---|---|---|
| Share price | $3.10 | $6.91 |
| Market cap | $591.37M | $634.88M |
| 1-day change | -9.09% | -5.99% |
| YTD return | -38.25% | -33.49% |
| 1-year return | -27.40% | -38.14% |
| 5-year return | -77.37% | -50.66% |
| EPS (TTM) | $-1.01 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | $-206.69M | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $7.18 | $13.90 |
| 52-week low | $3.07 | $6.75 |
| Distance from 52-week high | -56.82% | -50.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.39% | +357.60% |
| Average volume | 3.36M | 2.10M |
| Shares outstanding | 190.76M | 91.88M |
| Employees | 97 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed KURA by 10.7 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ANNX vs KURA FAQ
Which is bigger, Annexon or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $591.37M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or KURA?
ANNX returned -27.40% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.